Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Trial details
- Registry ID
- NCT07146022
- Drugs studied
- VDPHL01 BID, VDPHL01 QD
TrialRedline tracks 5 clinical trials sponsored by Veradermics, Inc.: 2 Phase 3, 1 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022 | VDPHL01 BID, VDPHL01 QD | Active not recruiting | 2027-06Estimated |
| Safety and Efficacy of VDPHL01 in Males With AGANCT06972264 | VDPHL01 | Active not recruiting | 2026-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of VDPHL01 in Males With AGANCT06724614 | VDPHL01 | Active not recruiting | 2026-02Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365 | VDPHL01 | Active not recruiting | 2026-08Estimated |
| Safety and Efficacy of VDMN-21 Patch in Subjects With Common WartsNCT05799157 | VDMN-21 Patch High Dose, VDMN-21 Patch Low Dose, Vehicle Patch | Completed | 2025-02-25Actual |
Names as written in the registry records.
NCT07146022 · Veradermics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06972264 · Veradermics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT07146022 · Veradermics, Inc.
Before: Mar 2027. After: Jun 2027.